# Hikma Ventures

Hikma Ventures is a Venture Capital based in London, United Kingdom.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** London, United Kingdom
- **Region:** Europe
- **Address:** London, United Kingdom
- **Founded:** 2015
- **Assets under management:** $100M–$500M (Altss estimate)
- **Website:** hikmaventures.com
- **LinkedIn:** https://www.linkedin.com/company/hikma-ventures

## Regulatory record

- **Reports private funds:** No

## About

Hikma Ventures is the strategic venture capital arm of Hikma Pharmaceuticals, investing in innovative digital health and life sciences companies worldwide. It invests in disruptive technologies and meaningful companies where there is a true strategic advantage both for Hikma and portfolio companies. The firm is investment stage-agnostic with a preference for Series A and beyond, with an average ticket size of up to $5 million per company per round.

## Sectors

- Digital Health
- Enterprise Software
- AI/ML

## People

- Lana Ghanem — Managing Director

## Questions

### How does Hikma Ventures source proprietary deal flow?

Hikma Ventures leans heavily on Hikma Pharmaceuticals' operating footprint in North America and the Middle East for sourcing. The team gains early looks at health-tech startups through the parent's relationships with hospital systems, generics buyers, and regulatory bodies. The firm also participates in traditional VC networks across London and Silicon Valley for enterprise software and AI exposure.

### Does Hikma Ventures participate in fund commitments or only direct deals?

The firm primarily executes direct deals, taking minority equity positions in Seed through Series B rounds. There is no public indication of a fund-of-funds program. The capital is drawn directly from Hikma Pharmaceuticals' balance sheet, so structures tend toward direct minority investments rather than LP commitments to outside managers.

### What investment stages does Hikma Ventures typically target?

Seed, Series A, and Series B rounds form the core stage mandate. The firm occasionally participates in later growth rounds for portfolio companies, but its stated focus is early-stage to growth-stage, aligning with corporate venture capital norms where early engagement maximizes both financial return potential and strategic insight for the parent.

### How is Hikma Ventures related to Hikma Pharmaceuticals?

Hikma Ventures is wholly owned and funded by Hikma Pharmaceuticals, the London-listed, FTSE 100 generics and branded medicines company. It functions as the corporate venture capital division, with its $250 million investment capacity coming directly from the parent's treasury function rather than from external limited partners.

### Where does Hikma Ventures deploy geographically?

The firm invests primarily in North America and EMEA, mirroring Hikma Pharmaceuticals' operational base. The US and UK are both active hunting grounds, with the Middle East emerging as a region of interest aligned with the parent's expanding manufacturing footprint there.

### Which sectors does Hikma Ventures explicitly avoid?

Hikma Ventures does not publicly maintain an exclusion list, but its mandate is tightly drawn around digital health, enterprise software, and AI/ML — sectors directly relevant to Hikma Pharmaceuticals' manufacturing, distribution, and clinical workflows. Deep-tech hardware, consumer apps, and therapeutics development fall outside its observed investment pattern.

## Related profiles

- [Hike Ventures](https://altss.com/profile/hike-ventures)
- [Hilco Brands](https://altss.com/profile/hilco-brands)

---

Last updated: 2026-08-11T15:06:57.816Z

Canonical page: https://altss.com/profile/hikma-ventures

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology